Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) EBITDA (2020 - 2026)

Treace Medical Concepts filings provide 6 years of EBITDA readings, the most recent being -$9.4 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 1480.67% to -$9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$59.0 million, a 5.77% decrease, with the full-year FY2025 number at -$59.0 million, down 5.77% from a year prior.
  • EBITDA hit -$9.4 million in Q4 2025 for Treace Medical Concepts, up from -$16.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$595000.0 in Q4 2024 to a low of -$21.3 million in Q2 2024.
  • Median EBITDA over the past 5 years was -$12.3 million (2022), compared with a mean of -$11.2 million.
  • Biggest five-year swings in EBITDA: plummeted 8566.67% in 2021 and later surged 90.03% in 2024.
  • Treace Medical Concepts' EBITDA stood at -$5.6 million in 2021, then grew by 20.69% to -$4.4 million in 2022, then plummeted by 34.49% to -$6.0 million in 2023, then surged by 90.03% to -$595000.0 in 2024, then crashed by 1480.67% to -$9.4 million in 2025.
  • The last three reported values for EBITDA were -$9.4 million (Q4 2025), -$16.3 million (Q3 2025), and -$17.4 million (Q2 2025) per Business Quant data.